Pages that link to "Q73906894"
Jump to navigation
Jump to search
The following pages link to Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators (Q73906894):
Displaying 50 items.
- Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond (Q22251042) (← links)
- Ginkgo biloba for acute ischaemic stroke (Q24245759) (← links)
- Excitatory amino acid antagonists for acute stroke (Q24248015) (← links)
- Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults (Q24558984) (← links)
- Neuroprotection for ischemic stroke: past, present and future (Q24645185) (← links)
- Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials (Q24793478) (← links)
- Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial (Q24804442) (← links)
- Ion channels as drug targets in central nervous system disorders (Q27004533) (← links)
- Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial (Q28165227) (← links)
- Stroke, dementia, and drug delivery (Q28166505) (← links)
- Management of acute stroke (Q28196668) (← links)
- Excitotoxic and Excitoprotective Mechanisms: Abundant Targets for the Prevention and Treatment of Neurodegenerative Disorders (Q28202177) (← links)
- Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study (Q28222300) (← links)
- Glutamate receptor ion channels: structure, regulation, and function (Q28290774) (← links)
- The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success (Q28394257) (← links)
- Hypoxia Induces an Increase in Intracellular Magnesium via Transient Receptor Potential Melastatin 7 (TRPM7) Channels in Rat Hippocampal Neurons in Vitro (Q28578811) (← links)
- Knockdown and overexpression of NR1 modulates NMDA receptor function. (Q30451702) (← links)
- Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales (Q30497328) (← links)
- High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial (Q30572344) (← links)
- Characterisation of gene expression changes following permanent MCAO in the rat using subtractive hybridisation. (Q31006509) (← links)
- The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. (Q31150630) (← links)
- A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke (Q31924104) (← links)
- Predicting recovery after intracerebral hemorrhage--an external validation in patients from controlled clinical trials (Q33420859) (← links)
- Molecular Dissection of Cyclosporin A's Neuroprotective Effect Reveals Potential Therapeutics for Ischemic Brain Injury (Q33772181) (← links)
- The role of canonical transient receptor potential channels in seizure and excitotoxicity (Q33883856) (← links)
- Stroke management (Q33928297) (← links)
- A radical approach to stroke therapy (Q33944177) (← links)
- NMDA receptor subunits: diversity, development and disease (Q33950711) (← links)
- Cellular functions of transient receptor potential channels (Q34020976) (← links)
- Glutamate receptors, neurotoxicity and neurodegeneration (Q34103957) (← links)
- Medical management of stroke (Q34187207) (← links)
- Neuroprotective potential of ionotropic glutamate receptor antagonists. (Q34209297) (← links)
- Neuroprotection for ischaemic stroke: an unattainable goal? (Q34313475) (← links)
- The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke (Q34410882) (← links)
- Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging (Q34458418) (← links)
- Migraine prophylaxis, ischemic depolarizations, and stroke outcomes in mice (Q34771803) (← links)
- Cyclin-dependent kinases as potential targets to improve stroke outcome. (Q34792871) (← links)
- NMDA receptor pathways as drug targets (Q34982270) (← links)
- Neuroprotective agents for the treatment of acute ischemic stroke (Q35036473) (← links)
- Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies. (Q35096123) (← links)
- Reprogramming the host response in bacterial meningitis: how best to improve outcome? (Q35176266) (← links)
- Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects (Q35202428) (← links)
- The added value of ordinal analysis in clinical trials: an example in traumatic brain injury. (Q35558241) (← links)
- A New Look At Glutamate and Ischemia: Nmda Agonist Improves Long-Term Functional Outcome In A Rat Model of Stroke (Q35588323) (← links)
- New considerations in the design of clinical trials for traumatic brain injury (Q35889519) (← links)
- What do we (not) know about the management of blood pressure in acute stroke? (Q35930124) (← links)
- Non-selective cation channels, transient receptor potential channels and ischemic stroke (Q36003275) (← links)
- Clinical trials for cytoprotection in stroke (Q36045223) (← links)
- Why have neuro-protectants failed?: lessons learned from stroke trials. (Q36245471) (← links)
- Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia (Q36260781) (← links)